Clinical Trials Logo

Injection Drug Use clinical trials

View clinical trials related to Injection Drug Use.

Filter by:
  • None
  • Page 1

NCT ID: NCT04427202 Completed - HIV Clinical Trials

Ending Transmission of HIV, HCV, and STDs and Overdose in Rural Communities of People Who Inject Drugs (ETHIC)

ETHIC
Start date: August 14, 2020
Phase: N/A
Study type: Interventional

This study will evaluate the referral to harm reduction services (HRS) including syringe services, naloxone overdose prevention, substance use treatment referral, HIV, HCV, and STD testing and referral and linkage to care through capacity building of existing programs through client services data.

NCT ID: NCT03949764 Active, not recruiting - Hepatitis C Clinical Trials

The Kentucky Viral Hepatitis Treatment Study

KeY Treat
Start date: September 23, 2019
Phase: Phase 4
Study type: Interventional

The overarching goal of the Kentucky Viral Hepatitis Treatment Project (KeY Treat) is to increase hepatitis C virus (HCV) treatment access and delivery in a rural Appalachian community, which is in the midst of the opioid/hepatitis C (HCV) syndemic. KeY Treat is a clinical research study seeking to determine whether removing barriers (cost, insurance, specialist, abstinence) associated with accessing direct-acting antivirals (DAAs) for the treatment of HCV will impact health in Perry County, Kentucky.

NCT ID: NCT01761110 Completed - Opioid Dependence Clinical Trials

Pilot Test of a Community-based Buprenorphine Treatment Intervention

Start date: December 2012
Phase: N/A
Study type: Interventional

The main goal of this study is to pilot test the community-based buprenorphine treatment (CBBT) intervention, examining buprenorphine treatment initiation, opioid use, and HIV risk behaviors. Two groups of participants will be followed for 60 days, with 3 research visits. One group will be enrolled prior to the CBBT intervention (pre-intervention), and one group after the CBBT intervention (post-intervention). Data sources will include questionnaires, urine toxicology tests, and medical record data. Investigators hypothesize that compared to the participants in the pre-intervention group, participants in the post-intervention group will be more likely to initiate buprenorphine treatment, reduce opioid use, and reduce high-risk HIV risk behaviors.